Welcome to the Ultimate Neuroscience Lab: Your Smartphone

By SharpBrains | September 30, 2021

Wel­come to a new edi­tion of Sharp­Brains’ e‑newsletter, fea­tur­ing this time six sci­en­tif­ic reports and indus­try resources plus a fun illu­sion. #1. Top 10 Men­tal Health Inno­va­tions to Watch: Spe­cial SciAm/ WEF report Hop­ing you enjoy the great series over at Sci­en­tif­ic Amer­i­can and espe­cial­ly #7, titled Wel­come to the Ulti­mate Neu­ro­science Lab: Your Smartphone,…

Read More

Study: Fewer than 1% of geriatric patients with cognitive complaints met Aduhelm research trial criteria. What can we expect about its real-world safety?

By SharpBrains | September 7, 2021

Bio­gen’s Aduhelm label far exceeds clin­i­cal tri­al pop­u­la­tion, study says. That could bring real-world sur­pris­es (Fierce Phar­ma): While the chat­ter sur­round­ing Biogen’s con­tro­ver­sial Alzheimer’s med Aduhelm has large­ly been cen­tered on a piv­otal Medicare reim­burse­ment deci­sion as of late, ana­lysts are point­ing to one new study that sug­gests there may be “room for sur­pris­es” when…

Read More

Finally, growing awareness of chemotherapy-induced cognitive deficits

By SharpBrains | May 29, 2014

Brain activ­i­ty changes seen after chemo (Reuters): “For some women with breast can­cer, changes in brain activ­i­ty while mul­ti­task­ing could explain “chemo brain” – reduced men­tal func­tion­ing that many expe­ri­ence after chemother­a­py, Bel­gian researchers say. “Cog­ni­tive com­plaints of peo­ple increase with chemother­a­py and 

Read More